Business
HeartBeam Reports Second Quarter 2022 Financial Results
Company Remains on Track for FDA Submissions of the HeartBeam AIMI™ Software Platform for the Emergency Department in Q3 2022 & AIMIGo™, the Telehealth
About this update from Heartbeam, Inc.
[{"type":"text","content":"\nCompany Remains on Track for FDA Submissions of the HeartBeam AIMI™ Software Platform for the Emergency Department in Q3 2022 & AIMIGo™, the Telehealth Solution, in Q4 2022\n\nAcquires Source Code Access Under the LivMor Partnership Agreement that will be Used to Build a Company-branded Version of the LIVMOR’s Halo+ FDA Cleared Turnkey Solution for Remote Patient Monitoring to Connect Physicians and Patients.\n\nManagement to Host Webcast and Conference Call Today At 4:30 p.m. ET\n\n SANTA CLARA, Calif.--(BUSINESS WIRE)--\nHeartBeam, Inc. (NASDAQ: BEAT), a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for heart attack detection, has reported its financial and operational results for the second quarter ended June 30, 2022.\n\nSecond Quarter 2022 Operational Highlights\n\n\nExpanded the addressable patient population for the Company’s HeartBeam AIMI™ software platform to provide access to a broader patient population in the Emergency Room\n\n\nSubmission of HeartBeam AIMI platform to FDA expected on or about August 15, 2022\n\n\nSupplemented LIVMOR partnership with source code acquisition for the HeartBeam branded version of the FDA Registered LIVMOR Halo+ Portal used with both of the Company’s products\n\n\nAppointed healthcare and cardiac industry veteran, Ken Persen, to the role of Chief Technology Officer\n\n\nSelected as winner of the annual Cardiovascular Innovations (CVI) 2022 Innovation Summit and Shark Tank Competition, an annual awards program recognizing state-of-the-art cardiac technologies\n\n\nPresented at investor conferences including the H.C. Wainwright Global Investment Conference and the LD Micro Invitational XII Conference\n\n\nManagement Commentary\n\n“The second quarter of 2022 delivered steady advancement along our commercialization pathway, including HeartBeam AIMI™ product submission for FDA clearance in the very near future. We are also very pleased with the rapid progress in getting our core product, the AIMIGo™ containing 3D vector ECG collection device prepared for FDA submission in Q4 of this year,” said Branislav Vajdic, PhD, Chief Executive Officer and Founder of HeartBeam. “We continue to have strong conviction in our HeartBeam AIMI software platform technology and AIMIGo, our end-to-end telemedicine solution, and their potential to offer more accur...